key: cord-0712255-i0vxixf3 authors: Pei, Shiyao; Yuan, Xi; Zhimin Zhang, Zhimin; Run Yao, Run; Xie, Yubin; Minxue Shen, Minxue; Bijuan Li, Bijuan; Chen, Xiang; Yin, Mingzhu title: Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences date: 2020-04-11 journal: nan DOI: 10.1101/2020.04.07.20056440 sha: 2cc90bf722a8a4456cf6e7ee46b9bfe8da42bc3c doc_id: 712255 cord_uid: i0vxixf3 The COVID-19 is currently spreading around the world, which has posed significant threats to global health and economy. Convalescent plasma is confirmed effective against the novel corona virus in preliminary studies. In this paper, we first described the therapeutic schedule, antibody detection method, indications, contraindications of the convalescent plasmas, and reported the operability of the treatment by case study. In December 2019, pneumonia associated with a novel corona virus 2019 (COVID-19) caused an outbreak, which has posed significant threats to global health and economy 1 China. To share Chinese experience with the world and to standardize the treatment, we summarized the therapeutic schedule of the convalescent plasmas as follows (Fig.1 ). . CC-BY-NC 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.07.20056440 doi: medRxiv preprint 1.1 Inclusion Criteria (All six criteria must be met) More than 3 weeks after the onset of symptoms of the COVID-19 and complete resolution of symptoms at least 14 days prior to donation. In accordance with relieved isolation and discharge standards following the latest version of the therapeutic schedule. Age: 18 -55 years old. Weight: male≥50kg, female≥45kg. No history of blood-transmitted diseases. Eligible donors must be assessed by clinicians according to treatment. With a history of pregnancy or transfusion whose HNA antibody and HLA antibody are positive. Individual's physical condition is not eligible assessed by clinicians. The interval between plasma collection should be more than two weeks. . CC-BY-NC 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint The novel coronavirus nucleic acid test is negative. Defined the titer of novel coronavirus-specific IgG antibody: serum/plasma of antibodies titer higher than 1:160. Hepatitis B surface antigen, hepatitis C antibody, HIV antibody, and Treponema pallidum antigen test were all negative. Alanine aminotransferase is well within the normal ranges. . CC-BY-NC 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.07.20056440 doi: medRxiv preprint Patients with long-term (more than 4 weeks) positive of novel coronavirus nucleic acid test (for details please refer to patient 2 in Fig.2 ). Congenital IgA deficiency. According to the principle of cross-matching of blood, ABO homogenous plasma is preferred. A slow infusion is required at the first 15 minutes in order to pay attention to the occurrence of adverse reactions of blood transfusion. Here we show the outcomes of three individual patients with convalescent plasma transfusion (Fig.2) , and the characteristics of the donor/receiver are shown in the supplementary table 2 (The participants gave their written informed consent and approved by the hospital ethics committee). The first patient was treated by convalescent plasma on the 12 th day of admission, the viral nucleic acid test became negative and the critical illness turned to severe. After the second therapy was conducted, . CC-BY-NC 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.07.20056440 doi: medRxiv preprint the patient had improved significantly and the discharge criteria were met on 26th day. We can learn from this case that convalescent plasma treatment can quickly turn the viral nucleic acid test negative and significantly reduced symptoms. The second case was a patient whose nucleic acid test was consistently positive with moderate symptoms, after treatment on 27 th day, the viral nucleic acid test turned negative four days later. Therefore, in order to save medical resources and reduce the transmission of infection, it is advisable to use convalescent plasma treatment on patients with long-term (more than 4 weeks) positive nucleic acid test of novel coronavirus. In the third case, the plasma donor was a 51-year-old woman with a history of pregnancy (supplementary table 2 Additionally, viral load after convalescent plasma treatment was significantly lower on days 3, 5, and 7 after intensive care unit admission 8 . What's more, we found that patients with long-term positive nucleic acid test of novel coronavirus turn negative earlier after convalescent plasma treatment than those without convalescent plasma treatment. Furthermore, asymptomatic patients with hypoimmunity, such as the elderly, children and patients with underlying diseases such as diabetes, hepatitis, AIDS, heart disease, tuberculosis, malignant tumor, etc., preferred to use . CC-BY-NC 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. No. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study WHO.Coronavirus disease COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease Clinical treatment of COVID-19 Convalescent Plasma (the second trial edition) FDA. Investigational covid-19 convalescent plasma-emergency INDs Convalescent Plasma to Treat COVID-19: Possibilities and Challenges Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clinical microbiology and infection : the official publication of the European Society of Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of All authors declare no competing interests. We thank all the hospital staff members for their efforts in collecting the information that used in this study; thank the patients who participated in . CC-BY-NC 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.07.20056440 doi: medRxiv preprint this study, their families, and the medical, nursing, and research staff at the study centers. No additional data are available.. CC-BY-NC 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.07.20056440 doi: medRxiv preprint author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.07.20056440 doi: medRxiv preprint